Clinical Trial Update: Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of frontline pembrolizumab plus valemetostat for PD-L1 positive, HPV-negative recurrent/metastatic squamous cell carcinoma of the head and nec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Sinonasal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• valemetostat (valemetostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sinonasal Cancer, Squamous Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: WITHDRAWN